Real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Asia–Pacific
Postmenopausal women with osteoporosis were more likely to be persistent and compliant with denosumab, compared with weekly oral alendronate.
Authors
- Tang Ching Lau (ORCID: https://orcid.org/0000-0003-1810-0926)
- Chung‐Hwan Chen (ORCID: https://orcid.org/0000-0001-8941-4792)
- Sheung Wai Law (ORCID: https://orcid.org/0000-0001-7923-0164)
- Dong‐Gune Chang (ORCID: https://orcid.org/0000-0001-6731-1063)
- Young‐Kyun Lee (ORCID: https://orcid.org/0000-0001-6564-4294)
- Cae Tolman
- See‐Hwee Yeo (ORCID: https://orcid.org/0000-0001-8658-8172)
- Peter R. Ebeling (ORCID: https://orcid.org/0000-0002-2921-3742)
- Laura Canals
- Jing Yu (ORCID: https://orcid.org/0000-0002-8694-8948)
- Shuang Huang
- Edith Lau
Institutions
- Kaohsiung Medical University (TW)
- National University of Singapore (SG)
- Chinese University of Hong Kong (HK)
- Seoul National University Hospital (KR)
- IQVIA (United Kingdom) (GB)
- State Administration of Foreign Exchange (CN)
- Jingdong (China) (CN)
- Inje University Sanggye Paik Hospital (KR)
- Monash Health (AU)
- Amgen (Australia) (AU)
- Amgen (Switzerland) (CH)
- Kaohsiung Municipal Ta-Tung Hospital (TW)
- IQ Solutions (US)
- Monash University (AU)
Publication Details
- Journal
- Journal of Bone and Mineral Metabolism
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1007/s00774-025-01663-2
- Citations
- 2
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- Amgen